Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes

[1]  J. Tamargo,et al.  Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[3]  D. Escande,et al.  Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. , 2001, The Journal of pharmacology and experimental therapeutics.

[4]  D. Roden,et al.  Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.

[5]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[6]  T Liu,et al.  Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. , 2001, American journal of physiology. Heart and circulatory physiology.

[7]  C. January,et al.  [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.

[8]  J. Nerbonne,et al.  ERG proteins and functional cardiac I(Kr) channels in rat, mouse, and human heart. , 2001, Trends in cardiovascular medicine.

[9]  A. Moss,et al.  ISHNE Guidelines for Electrocardiographic Evaluation of Drug‐related QT Prolongation and Other Alterations in Ventricular Repolarization: Task Force Summary , 2001, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[10]  C. Antzelevitch.  Heterogeneity of cellular repolarization in LQTS: the role of M cells , 2001 .

[11]  Focus on issues in measuring and interpreting changes in the QTc interval duration , 2001 .

[12]  M. Rosen.  Isolated tissue models and proarrhythmia , 2001 .

[13]  D. Escande.  Inhibition of repolarizing ionic currents by drugs , 2001 .

[14]  I. Cavero,et al.  Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs , 2001 .

[15]  L. Carlsson.  Drug-induced torsade de pointes: the perspectives of industry , 2001 .

[16]  J. Bauman.  The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome , 2001 .

[17]  M. Näbauer,et al.  Diversity of ion channel expression in health and disease , 2001 .

[18]  G. Breithardt,et al.  Clinical aspects of ventricular arrhythmias associated with QT prolongation , 2001 .

[19]  James Kramer,et al.  Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs , 2001 .

[20]  B. Darpö,et al.  Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes , 2001 .

[21]  M. Drici.  Influence of gender on drug-acquired long QT syndrome , 2001 .

[22]  K. Greenlund,et al.  Impaired Fasting Glucose, Diabetes Mellitus, and Cardiovascular Disease Risk Factors are Associated with Prolonged QTc Duration. Results from the Third National Health and Nutrition Examination Survey , 2001, Journal of cardiovascular risk.

[23]  P. Kowey,et al.  Phase 2 Early Afterdepolarization as a Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-QT Syndrome: Direct Evidence From Intracellular Recordings in the Intact Left Ventricular Wall , 2001, Circulation.

[24]  J. Reiffel,et al.  Importance of QT Interval Determination and Renal Function Assessment During Antiarrhythmic Drug Therapy , 2001, Journal of cardiovascular pharmacology and therapeutics.

[25]  Elisabetta Poluzzi,et al.  Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus , 2001, European Journal of Clinical Pharmacology.

[26]  Gea-Ny Tseng,et al.  IKr: The hERG Channel , 2001 .

[27]  A. Good,et al.  3-D pharmacophores in drug discovery. , 2001, Current pharmaceutical design.

[28]  Hua-rong Lu,et al.  Female Gender is a Risk Factor for Drug‐Induced Long QT and Cardiac Arrhythmias in an In Vivo Rabbit Model , 2001, Journal of cardiovascular electrophysiology.

[29]  T J Campbell,et al.  HERG K+ channels: friend and foe. , 2001, Trends in pharmacological sciences.

[30]  S. O’Donoghue,et al.  Levofloxacin Induced Polymorphic Ventricular Tachycardia with Normal QT Interval , 2001, Pacing and clinical electrophysiology : PACE.

[31]  D. Fife,et al.  Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ‘dear doctor’ letters , 2001, Pharmacoepidemiology and drug safety.

[32]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[33]  C. January,et al.  Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. , 2001, Molecular pharmacology.

[34]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[35]  M. Maggini,et al.  Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. , 2001, JAMA.

[36]  M Malik,et al.  Problems of Heart Rate Correction in Assessment of Drug‐Induced QT Interval Prolongation , 2001, Journal of cardiovascular electrophysiology.

[37]  J. Towbin,et al.  Molecular biology and the prolonged QT syndromes. , 2001, The American journal of medicine.

[38]  A. Potti,et al.  Fluconazole-Induced Torsade de Pointes , 2001, The Annals of pharmacotherapy.

[39]  J. Pezzullo,et al.  Drug-induced QT prolongation in women during the menstrual cycle. , 2001, JAMA.

[40]  R. Owens.  Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes , 2001, Pharmacotherapy.

[41]  M. Yamamoto,et al.  Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  P. Puddu,et al.  Screening for drug-induced (acquired) long QT syndrome: is it time to apply new methods? , 2001, European heart journal.

[43]  D. Escande,et al.  Dynamic analysis of the QT interval in long QT1 syndrome patients with a normal phenotype. , 2001, European heart journal.

[44]  J. Saul,et al.  Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia , 2001, Clinical pharmacology and therapeutics.

[45]  A J Camm,et al.  The QT Interval , 2010 .

[46]  W S Redfern,et al.  Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. , 2001, Cardiovascular research.

[47]  F. Lombardi.  QT dispersion: an inappropriate measure of a good concept , 2001 .

[48]  M. E. O'leary.  Inhibition of human ether-a-go-go potassium channels by cocaine. , 2001, Molecular pharmacology.

[49]  H. Wellens,et al.  Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. , 2001, European journal of pharmacology.

[50]  D. Roden,et al.  Sympathetic Activation Enhances QT Prolongation by Quinidine , 2001, Journal of cardiovascular electrophysiology.

[51]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[52]  A. Skanes,et al.  QT dispersion: an electrocardiographic derivative of QT prolongation. , 2001, American heart journal.

[53]  M. Drici,et al.  Is Gender a Risk Factor for Adverse Drug Reactions? , 2001, Drug safety.

[54]  J. Blumer,et al.  Safety of Antihistamines in Children , 2001, Drug safety.

[55]  O. Pongs,et al.  Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[56]  A J Camm,et al.  Evaluation of Drug-Induced QT Interval Prolongation , 2001, Drug safety.

[57]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[58]  Michael J. Goodman,et al.  Contraindicated use of cisapride: impact of food and drug administration regulatory action. , 2000, JAMA.

[59]  J. Sullivan,et al.  Potassium channels: molecular defects, diseases, and therapeutic opportunities. , 2000, Pharmacological reviews.

[60]  C Fisch,et al.  Centennial of the string galvanometer and the electrocardiogram. , 2000, Journal of the American College of Cardiology.

[61]  M. Malik,et al.  Measurement, interpretation and clinical potential of QT dispersion. , 2000, Journal of the American College of Cardiology.

[62]  H. Karagueuzian.  Consensus Statement from the Cardiac Nomenclature Study Group of Arrhythmias of the European Society of Cardiology, and the Task Force on Cardiac Nomenclature from the North American Society of Pacing and Electrophysiology on Living Anatomy of the Atrioventricular Junctions , 2000 .

[63]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  O. Pongs,et al.  Effects of fluoroquinolones on HERG currents. , 2000, European journal of pharmacology.

[65]  D J Sheridan,et al.  Drug-induced proarrhythmic effects: assessment of changes in QT interval. , 2000, British journal of clinical pharmacology.

[66]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Oliver,et al.  The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. , 2000, British journal of clinical pharmacology.

[68]  Prolongation of QT interval corrected for heart rate by Bazett's equation and linear formula as predictor of arrhythmic events after myocardial infarction. , 2000, The American journal of cardiology.

[69]  C. Antzelevitch,et al.  Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. , 2000, Circulation.

[70]  A J Camm,et al.  QT Dispersion Does Not Represent Electrocardiographic Interlead Heterogeneity of Ventricular Repolarization , 2000, Journal of cardiovascular electrophysiology.

[71]  D. Roden.  Acquired Long QT Syndromes and the Risk of Proarrhythmia , 2000, Journal of cardiovascular electrophysiology.

[72]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[73]  G. Ford,et al.  CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. , 2000, British journal of clinical pharmacology.

[74]  J. Schwartz.  The electrocardiographic QT interval and its prolongation in response to medications: differences between men and women. , 2000, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.

[75]  L. Dreifus,et al.  Cocaine abuse: repolarization abnormalities and ventricular arrhythmias. , 2000, The American journal of the medical sciences.

[76]  P. O. Lim,et al.  QT dispersion in medicine: electrophysiological holy grail or fool's gold? , 2000, QJM : monthly journal of the Association of Physicians.

[77]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[78]  D M Roden,et al.  The long QT syndromes: genetic basis and clinical implications. , 2000, Journal of the American College of Cardiology.

[79]  S. Priori,et al.  Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias , 2000, Journal of cardiovascular electrophysiology.

[80]  M. Malik.  QT dispersion: time for an obituary? , 2000, European heart journal.

[81]  Senén Barro,et al.  A new approach for TU complex characterization , 2000, IEEE Transactions on Biomedical Engineering.

[82]  H. Wellens,et al.  Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. , 2000, Cardiovascular research.

[83]  H Tie,et al.  The heart of psychotropic drug therapy , 2000, The Lancet.

[84]  J. Idle.  The heart of psychotropic drug therapy , 2000, The Lancet.

[85]  K. Overall,et al.  Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration. , 2000, Journal of the American Veterinary Medical Association.

[86]  Rank Power of Metrics Used to Assess QTc Interval Prolongation by Clinical Trial Simulation , 2000, Journal of clinical pharmacology.

[87]  J. Camm,et al.  Risk of torsades de pointes with non-cardiac drugs , 2000, BMJ : British Medical Journal.

[88]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[89]  S. Ayis,et al.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.

[90]  M. Gralinski.  The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. , 2000, Journal of pharmacological and toxicological methods.

[91]  S. Y. Wang,et al.  Block of human heart hH1 sodium channels by amitriptyline. , 2000, The Journal of pharmacology and experimental therapeutics.

[92]  D. Greenblatt,et al.  Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.

[93]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[94]  C. Vannier,et al.  The preclinical assessment of the risk for QT interval prolongation. , 2000, Therapie.

[95]  D. Ferguson,et al.  QSAR and CoMFA: a perspective on the practical application to drug discovery. , 2000, Drug Design and Discovery.

[96]  H. Wellens,et al.  Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. , 1999, Circulation.

[97]  L. Horan,et al.  Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. , 1999, Journal of cardiovascular pharmacology.

[98]  E. Kanoupakis,et al.  Idiopathic prolonged QT interval and QT dispersion: the effects of propofol during implantation of cardioverter-defibrillator. , 1999, European journal of anaesthesiology.

[99]  G. Nickenig,et al.  Long QT Syndrome and Torsade de Pointes in a Patient Receiving Fluconazole , 1999, Annals of Internal Medicine.

[100]  P. Gretener,et al.  Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs , 1999, Experimental and Toxicologic Pathology.

[101]  M E Frisse,et al.  Impact of a Web-based clinical information system on cisapride drug interactions and patient safety. , 1999, Archives of internal medicine.

[102]  M. Malik,et al.  Comparison of Formulae for Heart Rate Correction of QT Interval in Exercise Electrocardiograms , 1999, Pacing and clinical electrophysiology : PACE.

[103]  B. J. Middleton,et al.  Relationship between QT interval and heart rate in Alderley Park beagles , 1999, Veterinary Record.

[104]  R. -. Wang,et al.  pH-dependent cocaine-induced cardiotoxicity. , 1999, The American journal of emergency medicine.

[105]  Cavero,et al.  QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.

[106]  C. January,et al.  Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.

[107]  Z. Ungvari,et al.  Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? , 1999, Current medicinal chemistry.

[108]  T. Takano,et al.  Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease , 1999, European Journal of Clinical Pharmacology.

[109]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[110]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[111]  P. Bonate,et al.  Assessment of QTc Prolongation for Non‐Cardiac‐Related Drugs from a Drug Development Perspective , 1999, Journal of clinical pharmacology.

[112]  H. Crijns,et al.  QT lengthening and life-threatening arrhythmias associated with fexofenadine , 1999, The Lancet.

[113]  T. Mitsui,et al.  QT prolongation and torsades de pointes induced by an antifungal agent, D0870, in conscious dogs. , 1999, Toxicology.

[114]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.

[115]  S Nattel,et al.  The Molecular and Ionic Specificity of Antiarrhythmic Drug Actions , 1999, Journal of cardiovascular electrophysiology.

[116]  V. Segarra,et al.  Computer-Assisted Comparison of the Structural and Electronic Dispositions of Ebastine and Terfenadine , 1999, Drug safety.

[117]  A. S. Davis.  The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods , 1998, Human & experimental toxicology.

[118]  C. Hoe,et al.  The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[119]  B. Surawicz,et al.  U Wave: Facts, Hypotheses, Misconceptions, and Misnomers , 1998, Journal of cardiovascular electrophysiology.

[120]  A. Brown,et al.  Blockade of HERG and Kv1.5 by ketoconazole. , 1998, The Journal of pharmacology and experimental therapeutics.

[121]  G. Breithardt,et al.  Experimental models of torsade de pointes. , 1998, Cardiovascular research.

[122]  M. Omata,et al.  Ostensible day-night difference of QT prolongation during long-term treatment with antiarrhythmic drugs: reappraisal of the law of "regression to the mean". , 1998, Journal of cardiovascular pharmacology.

[123]  C. January,et al.  Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. , 1998, Molecular pharmacology.

[124]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[125]  A. Brown,et al.  Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.

[126]  D. Fedida,et al.  The 1997 Stevenson Award Lecture. Cardiac K+ channel gating: cloned delayed rectifier mechanisms and drug modulation. , 1998, Canadian journal of physiology and pharmacology.

[127]  M. Contin,et al.  Q‐T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors , 1998, Hepatology.

[128]  T. Mitsui,et al.  QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. , 1997, Journal of pharmacological and toxicological methods.

[129]  M. Q. Zhang,et al.  Chemistry Underlying the Cardiotoxicity of Antihistamines , 1997 .

[130]  P. Coumel,et al.  KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. , 1997, Circulation.

[131]  D M Roden,et al.  Structure and function of cardiac sodium and potassium channels. , 1997, The American journal of physiology.

[132]  K. Hashimoto,et al.  Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. , 1997, Toxicology and applied pharmacology.

[133]  B Attali,et al.  The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes , 1997, British journal of pharmacology.

[134]  M. Riccio,et al.  An Animal Model of Spontaneous Arrhythmic Death , 1997, Journal of cardiovascular electrophysiology.

[135]  A. Petrou,et al.  The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans. , 1996, European journal of anaesthesiology.

[136]  A. Moss.  Correct the QT Interval Correctly: QTc Should be Expressed in the Same Unit as the QT Interval , 1996, Pacing and clinical electrophysiology : PACE.

[137]  F. Lang,et al.  Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole , 1996, FEBS letters.

[138]  J. Eledjam,et al.  Comparative Electrophysiologic and Hemodynamic Effects of Several Amide Local Anesthetic Drugs in Anesthetized Dogs , 1996, Anesthesia and analgesia.

[139]  J. Bauman,et al.  QT Interval Prolongation and Torsades de Pointes Due to Erythromycin Lactobionate , 1995, Pharmacotherapy.

[140]  K. Yano,et al.  Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. , 1995, Circulation.

[141]  J. Weiss,et al.  The missing second: what is the correct unit for the Bazett corrected QT interval? , 1995, The American journal of cardiology.

[142]  A. Murray,et al.  Errors in manual measurement of QT intervals. , 1994, British heart journal.

[143]  P Jaillon,et al.  Rate-corrected QT interval: techniques and limitations. , 1993, The American journal of cardiology.

[144]  M. Ragagni,et al.  [Idiopathic long QT-syndrome. Changes in the duration of the QTC during anesthesia with propofol]. , 1993, Minerva anestesiologica.

[145]  A. Hiller,et al.  QT interval, heart rate and arterial pressures using propofol, thiopentone or methohexitone for induction of anaesthesia in children , 1993, Acta anaesthesiologica Scandinavica.

[146]  C. Hansch.  Quantitative structure-activity relationships and the unnamed science , 1993 .

[147]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.

[148]  H. Refsum,et al.  CHANGES IN VENTRICULAR FIBRILLATION THRESHOLD DURING ACUTE HYPOTHERMIA. A MODEL FOR FUTURE STUDIES , 1993, Journal of basic and clinical physiology and pharmacology.

[149]  M E Sullivan,et al.  An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. , 1992, Progress in medicinal chemistry.

[150]  L. Lindgren,et al.  QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia , 1990, Acta anaesthesiologica Scandinavica.

[151]  R S Reneman,et al.  An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. , 1989, Journal of pharmacological methods.

[152]  D. Sheridan,et al.  Generalized seizures as the presentation of flecainide toxicity. , 1989, European heart journal.

[153]  S. Giampaoli,et al.  Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: emphasis on the cubic root Fridericia's equation. , 1988, Journal of electrocardiology.

[154]  T. Peter,et al.  QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. , 1987, The American journal of cardiology.

[155]  R. Woestenborghs,et al.  Pharmacokinetics and tissue distribution of astemizole in the dog , 1986 .

[156]  J. Ruskin,et al.  Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. , 1985, The American journal of cardiology.

[157]  J. Tamargo,et al.  Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. , 1985, European journal of pharmacology.

[158]  M. Herman,et al.  QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration. , 1981, The Mount Sinai journal of medicine, New York.

[159]  Michael R. Greenberg,et al.  Chapter 1 – Theory, Methods, and Applications , 1978 .

[160]  W. Nelson,et al.  Evolutionary changes in the electrocardiogram of severe progressive hypothermia. , 1977, Journal of electrocardiology.

[161]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .

[162]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .